A Phase 1 interventional study of Nalmefene HCl injection and Naloxone HCl intranasal in Opioid Overdose, sponsored by Purdue Pharma LP. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Opiate Overdose with a site in United States — 8 open to participants now, 15 under way, none of them phase 3. Opiate Overdose · United States.
Among the 56 studies in Opiate Overdose with a site in United States, this one is the 37th largest by enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2022, is one of 6 in phase 1, and was the 49th registered.
70 studies on the registry are indexed under Opiate Overdose; 11 are open to participants now.
Browse Opiate Overdose studies →8 of the 56 studies in Opiate Overdose with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 19+
University of Illinois at Chicago · Sites in United States
Ages 18+ · Healthy volunteers
Drexel University · Sites in United States
Ages 18+ · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
Hartford Hospital · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Opiate Overdose studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 184 across 48 interventional studies indexed under Opiate Overdose.
Median enrollment 184 across the 44 interventional studies, 106 across the 12 observational. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under Purdue Pharma LP, one of the names counted as Knoa Pharma. Under that name alone:
Purdue Pharma LP is the lead sponsor of 58 studies on the registry; none are open to participants now.
Knoa Pharma has 3 studies filed under Opiate Overdose — fewer than ten, so there is no comparison to draw.
1 of the studies in Opiate Overdose with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05713695University of Massachusetts, WorcesterSupporting Treatment Access and Recovery Through Linkage and Support | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 56 studies in Opiate Overdose with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the pharmacodynamics (change in minute ventilation) of nalmefene when given as an autoinjector intramuscularly (IM; into the thigh) compared to naloxone when given intranasally (IN; into the nose) to healthy subjects with prior opioid exposure under steady state fentanyl concentrations (opioid agonism).
Key Inclusion Criteria include:
Key Exclusion Criteria include:
Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
Drug: Nalmefene HCl injection
Naloxone 4 mg for intranasal (IN) administration
Drug: Naloxone HCl intranasal
Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
Naloxone 4 mg for intranasal (IN) administration
Also known as: Narcan
Change in Minute Ventilation 5 Minutes From Opioid Induced Nadir
To assess the change in minute ventilation at 5 minutes of intramuscular nalmefene and intranasal naloxone reversal from the opioid induced nadir.
Time frame: 5 minutes after opioid antagonist administration
Change in Minute Ventilation at 2.5, 5, 10, 15, 20, 30, and 90 Minutes From Opioid Induced Nadir
To assess the time course of changes in minute ventilation of intramuscular nalmefene and intranasal naloxone reversal from the opioid induced nadir.
Time frame: Baseline, 2.5, 5, 10, 15, 20, 30, and 90 minutes after opioid antagonist administration
Maximum Plasma Concentration (Cmax)
Maximum plasma concentration of nalmefene and naloxone.
Time frame: up to 24 hours post-dose
Area Under the Curve (AUC0-2.5)
Area under the plasma concentration-time curve from time zero to 2.5 minutes
Time frame: 2.5 minutes post-dose
Area Under the Curve (AUC0-5)
Area under the plasma concentration-time curve from time zero to 5 minutes
Time frame: 5 minutes post-dose
Area Under the Curve (AUC0-10)
Area under the plasma concentration-time curve from time zero to 10 minutes
Time frame: 10 minutes post-dose
Area Under the Curve (AUC0-15)
Area under the plasma concentration-time curve from time zero to 15 minutes
Time frame: 15 minutes post-dose
Area Under the Curve (AUC0-20)
Area under the plasma concentration-time curve from time zero to 20 minutes
Time frame: 20 minutes post-dose
Area Under the Curve (AUCt)
Area under the plasma concentration-time curve from time zero to the time of last measurable concentration.
Time frame: up to 24 hours post-dose
Area Under the Curve (AUCinf)
Area under the plasma concentration-time curve from time zero to infinity.
Time frame: up to 24 hours post-dose
Time to Maximum Plasma Concentration (Tmax)
Time to maximum plasma concentration of nalmefene and naloxone.
Time frame: up to 24 hours post-dose
Time to First Measurable Plasma Concentration (Tlag)
Time to first measurable plasma concentration of nalmefene and naloxone.
Time frame: up to 24 hours post-dose
Half-life (T1/2)
Half life of nalmefene and naloxone.
Time frame: up to 24 hours post-dose
The first subject was dosed 03-October-2022 and the last subject completed the study 23-December-2022. The study was conducted at 1 site in the US.
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 13 | 0 | 0 |
| Completed | 13 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 13 | 0 | 0 |
| Completed | 13 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 0 | 12 | 12 |
| Completed | 0 | 12 | 12 |
| Not completed | 0 | 0 | 0 |
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 0 | 12 | 12 |
| Completed | 0 | 12 | 11 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 0 | 12 | 11 |
| Completed | 0 | 12 | 11 |
| Not completed | 0 | 0 | 0 |
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 0 | 12 | 11 |
| Completed | 0 | 12 | 11 |
| Not completed | 0 | 0 | 0 |
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 0 | 12 | 11 |
| Completed | 0 | 12 | 11 |
| Not completed | 0 | 0 | 0 |
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 0 | 12 | 11 |
| Completed | 0 | 11 | 11 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Milestone | Fentanyl Infusion | Sequence 1 (Test-Reference-Test-Reference) | Sequence 2 (Reference-Test-Reference-Test) |
|---|---|---|---|
| Started | 0 | 11 | 11 |
| Completed | 0 | 11 | 11 |
| Not completed | 0 | 0 | 0 |
To assess the change in minute ventilation at 5 minutes of intramuscular nalmefene and intranasal naloxone reversal from the opioid induced nadir.
| L/min | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Change in Minute Ventilation 5 Minutes From Opioid Induced Nadir | 4.42 ± 2.033 | 2.03 ± 0.992 |
To assess the time course of changes in minute ventilation of intramuscular nalmefene and intranasal naloxone reversal from the opioid induced nadir.
| L/min | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Baseline | 2.92 ± 1.254 | 3.02 ± 1.022 |
| 2.5 minutes | 2.00 ± 1.284 | 1.67 ± 1.046 |
| 5 minutes | 4.42 ± 2.033 | 2.03 ± 0.992 |
| 10 minutes | 3.97 ± 1.755 | 2.57 ± 1.364 |
| 15 minutes | 4.15 ± 1.990 | 2.79 ± 1.328 |
| 20 minutes | 4.00 ± 2.176 | 3.11 ± 1.160 |
| 30 minutes | 3.62 ± 1.820 | 2.92 ± 1.357 |
| 90 minutes | 2.74 ± 1.519 | 2.55 ± 0.994 |
Maximum plasma concentration of nalmefene and naloxone.
| ng/mL | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Maximum Plasma Concentration (Cmax) | 8.3576 ± 3.71139 | 5.6015 ± 2.30753 |
Area under the plasma concentration-time curve from time zero to 2.5 minutes
| ng*hr/mL | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Area Under the Curve (AUC0-2.5) | 0.0440 ± 0.03923 | 0.256 ± 0.03663 |
Area under the plasma concentration-time curve from time zero to 5 minutes
| ng*hr/mL | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Area Under the Curve (AUC0-5) | 0.2225 ± 0.13565 | 0.1002 ± 0.11542 |
Area under the plasma concentration-time curve from time zero to 10 minutes
| ng*hr/mL | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Area Under the Curve (AUC0-10) | 0.7576 ± 0.38147 | 0.3311 ± 0.27201 |
Area under the plasma concentration-time curve from time zero to 15 minutes
| ng*hr/mL | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Area Under the Curve (AUC0-15) | 1.2716 ± 0.52366 | 0.6300 ± 0.43256 |
Area under the plasma concentration-time curve from time zero to 20 minutes
| ng*hr/mL | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Area Under the Curve (AUC0-20) | 1.7479 ± 0.61346 | 0.9817 ± 0.61050 |
Area under the plasma concentration-time curve from time zero to the time of last measurable concentration.
| ng*hr/mL | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Area Under the Curve (AUCt) | 23.1620 ± 3.60968 | 13.4803 ± 2.78735 |
Area under the plasma concentration-time curve from time zero to infinity.
| ng*hr/mL | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Area Under the Curve (AUCinf) | 25.7412 ± 4.65028 | 13.4938 ± 2.87023 |
Time to maximum plasma concentration of nalmefene and naloxone.
| hour | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 0.2083 (0.062 to 1.017) | 0.6667 (0.167 to 1.000) |
Time to first measurable plasma concentration of nalmefene and naloxone.
| hour | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Time to First Measurable Plasma Concentration (Tlag) | 0.0527 ± 0.01912 | 0.0464 ± 0.01023 |
Half life of nalmefene and naloxone.
| hour | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|
| Half-life (T1/2) | 7.9754 ± 2.16550 | 1.6353 ± .050257 |
Collected over All serious adverse events and adverse events were collected from the signing of the informed consent for study participation through 30 days after the subject's last dose of study drug or within 30 days after the last study visit or follow-up phone call (up to approximately 78 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fentanyl Infusion | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| Nalmefene Hydrochloride (HCl) Injection | 0/23 (0%) | 0/23 (0%) | 20/23 (87%) |
| Narcan Intranasal | 0/24 (0%) | 0/24 (0%) | 18/24 (75%) |
| Event | Fentanyl Infusion | Nalmefene Hydrochloride (HCl) Injection | Narcan Intranasal |
|---|---|---|---|
| Feeling hotGeneral disorders | 1/13 | 11/23 | 4/24 |
| DysgeusiaNervous system disorders | 0/13 | 1/23 | 7/24 |
| NauseaGastrointestinal disorders | 1/13 | 6/23 | 5/24 |
| ChillsGeneral disorders | 0/13 | 6/23 | 0/24 |
| PruritusSkin and subcutaneous tissue disorders | 3/13 | 0/23 | 0/24 |
| HeadacheNervous system disorders | 0/13 | 5/23 | 5/24 |
| AllodyniaNervous system disorders | 0/13 | 5/23 | 2/24 |
| PalpitationsCardiac disorders | 0/13 | 4/23 | 0/24 |
| TinnitusEar and labyrinth disorders | 0/13 | 4/23 | 0/24 |
| DizzinessNervous system disorders | 2/13 | 4/23 | 1/24 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 39.1 ± 7.60 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 2 |
| Male | 22 |
| Ethnicity (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 11 |
| White | 10 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Dec 2022, 2 months.
Results were first posted in Jul 2025, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalmefene